Mechanisms of resistance to decitabine in the myelodysplastic syndrome. - Wikidata - awgldk - TriplyDB

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

http://www.wikidata.org/entity/Q33999539

about

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers Predicting response to epigenetic therapy Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells Established and emerging targeted therapies in the myelodysplastic syndromes.TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients Artesunate-enhanced apoptosis of human high-risk myelodysplastic cells induced by the DNA methyltransferase inhibitor decitabine.Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.Epigenetic synergy between decitabine and platinum derivatives Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia Digging deep into "dirty" drugs - modulation of the methylation machinery.Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.The myelodysplastic syndrome as a prototypical epigenetic disease CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Epigenetics of myelodysplastic syndromes.Novel drugs for older patients with acute myeloid leukemia.Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines Epigenetics: A primer for clinicians.Targeting the cancer epigenome for therapy.Epigenetic Determinants of Cancer.DNA Hypomethylating Drugs in Cancer Therapy.Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.Hypomethylation of let-7a-3 is associated with poor prognosis in myelodysplastic syndrome.Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.Choosing a hypomethylating agent in MDS: does gender matter?Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells

P2860

Q26743743-36EF663B-A435-4F11-96D1-D818531DDA25 Q27027751-E31CDFDD-6029-40F3-B28A-E03737EA6E32 Q28534843-49A0CB14-AAE0-4044-AC2A-17DC7786E73A Q28547322-A3E17FC7-6CB6-413A-945D-F5181C9E1C42 Q30245476-7D0CE09B-2685-4CFE-89C8-72F29D3ACED2 Q34398397-20D20FAA-431C-4CC1-8078-6314A0A74AF8 Q35681469-EC181F7B-C214-41D0-A8A9-41EFAE061EA1 Q35870211-A719A562-E75A-485B-A412-F53CA694518C Q36053915-B7CF133F-4DD6-499D-A353-04311ECBFE8D Q36290974-47BDE85A-D627-4F43-9617-A45FED9E2993 Q36502385-8A4DF31C-5A82-45B4-A2DA-DDFB852CEB96 Q36523796-DA904CE3-282C-486C-A787-6532A9B7CB7F Q36544042-3078E12C-DAFB-47F7-803B-579583715EEC Q36654373-73020109-D728-4948-95FF-1EC786483F6E Q36833557-B381F21F-9FB0-41CC-8FA7-3755349F632D Q36899731-D203FE95-CC5C-4165-ADC9-4BDFFF2912D6 Q37031262-4666A75C-F438-4B92-917A-74B94D408B09 Q37627821-31334378-C295-4884-8ACC-B26521F0B1FB Q37994505-A915AA4B-FB1D-49B8-B10A-968B4B537606 Q38160051-856F4975-555D-4290-98F6-7A2F321CC660 Q38163846-CD401095-A711-437D-BDA3-06703D0596C1 Q38241761-28CEA1C7-3717-4CD9-BFC2-B4ED9B2AFAF6 Q38407057-4C9EFF47-4ACA-43C5-907F-27CC8A53DC94 Q38762107-3CDCBC0E-7068-4924-86DE-B4424D734666 Q38770916-1A1A3216-BE30-456D-B71F-36458485768E Q38821103-F7124632-5A3A-4ACA-BCE5-D170F91ED1DB Q38837858-948C3AB9-6414-4CCF-9871-6C419ED01813 Q38979940-23B26AE4-841F-4C17-89FE-A94EFD5482E9 Q39527812-47AEB1C6-B6EE-46D4-A241-847CC9048393 Q47562352-45414959-7549-4EED-A03A-78E732786DB4 Q49596672-FB3936D4-4313-4070-BC59-657EFC388A6D Q49711997-0DC80058-D4F4-44DE-A45C-6871F830FFC6 Q53089094-44EB31EF-0DDC-4F7B-A79F-31555F122737 Q53652472-044F8185-40AB-4419-AC09-4BD0822085AF Q53698496-07B480E4-167A-4D75-BBCD-FB2072E9769D Q53810338-AC66F151-6840-420F-B287-13120A30D564 Q55433291-0AA25586-2657-46DA-95B7-C4B80012F8AD Q57461985-2DF5BFF3-75EB-4347-B31A-ECBFF75947DF

P2860

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

http://www.wikidata.org/entity/Q33999539

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

@ast

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

@en

type

label

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

@ast

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

@en

prefLabel

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

@ast

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

@en

P1433

Q33999539-8786E56C-77AE-4FA1-AF8A-CC81326EA530

P1476

Q33999539-A3DB71F0-98D7-4080-BD74-B251477748D7

P2093

Q33999539-16668577-B1FC-4109-9400-CCD47BD87E6B

Q33999539-4E39BAB0-A869-47A6-B880-D6CD46AF2585

Q33999539-5A2A6480-E5E4-4330-BF95-8AEF71BE184A

Q33999539-7E1137F3-953B-4815-B4C5-519D13C1DC8E

Q33999539-7ED18AB0-746C-485F-A71C-71253FF9EC58

Q33999539-859AE0E3-32D8-4411-B76F-8E08D1117D2F

Q33999539-A6F22058-1116-40D9-B5C1-63E36655D6D9

Q33999539-C0A55ADB-E8EC-4455-B092-D6278065CA3D

Q33999539-F41C528B-8F66-423E-93C7-6A87FBDB81A2

Q33999539-F5AD0E39-A9B9-40F3-9926-AF687D277AAA

P2860

Q33999539-086E0F97-4073-4321-BC7D-D69B8F2E075E

Q33999539-14E3C5B9-F2B6-421C-BB58-14B574FC420C

Q33999539-16BA8D87-E123-4D28-BE16-07EDB063F28C

Q33999539-1DB5DE1F-10E9-485C-9069-12F0D45EFF40

Q33999539-3A5CC52F-2E69-4AAD-B0E3-D12459E66484

Q33999539-3B9D4467-969D-4DD6-925E-76EF51DAAE03

Q33999539-3BEE5562-E4BF-4D9E-A058-A96A4E09100C

Q33999539-472B4AEE-32BA-4C0A-BBCC-D8517E81D546

Q33999539-4E83AC32-6C29-41FC-AE49-84CDD6F9A74B

Q33999539-5811C7F7-092E-4A26-8BAA-09535CCBB4E7

P304

Q33999539-D141DB0E-F193-485A-8091-172F0292E10D

P31

Q33999539-2812F5C8-6C0F-474C-B1CF-0145102512C2

P356

Q33999539-45A44DC5-843B-4325-81A5-3FAAAD3323F3

P407

Q33999539-0AF2F51A-8E16-49B4-873C-933875B2FC6F

P433

Q33999539-6C21D7F2-FCFB-457E-82B6-56B7E785EF70

P478

Q33999539-73F8483A-2C56-40C4-8E35-83B707A38DB7

P50

Q33999539-64F7653C-E7D3-4006-9704-9B00E9D7494F

Q33999539-984D49DD-43AA-4BA8-8D78-AC63C22941F8

Q33999539-B5AA7015-FCFC-46AB-B3A8-FF46364B65F2

P577

Q33999539-44BC285F-72A0-4F20-897D-134401DECF34

P5875

Q33999539-70FA4D73-7A22-462D-B529-259BBBBE15A9

P698

Q33999539-D883B08C-9E13-4EF9-95BA-8F91B4DBF5EE

P932

Q33999539-53B70C76-7E97-41C5-9BBE-73EF3F85E2F7

P356

JOURNAL.PONE.0023372

P1433

P1476

Mechanisms of resistance to decitabine in the myelodysplastic syndrome

@en

P2093

Hagop M Kantarjian

http://www.w3.org/2001/XMLSchema#string

Jaroslav Jelinek

http://www.w3.org/2001/XMLSchema#string

Jiali Si

http://www.w3.org/2001/XMLSchema#string

Jingmin Shu

http://www.w3.org/2001/XMLSchema#string

Nianxiang Zhang

http://www.w3.org/2001/XMLSchema#string

Rong He

http://www.w3.org/2001/XMLSchema#string

Samih El Ahdab

http://www.w3.org/2001/XMLSchema#string

Taichun Qin

http://www.w3.org/2001/XMLSchema#string

Woonbok Chung

http://www.w3.org/2001/XMLSchema#string

Xiaodan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

High sensitivity mapping of methylated cytosines

Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites

Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa

International scoring system for evaluating prognosis in myelodysplastic syndromes

Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine

Epigenetic inactivation of the miR-124-1 in haematological malignancies.

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

Widespread and tissue specific age-related DNA methylation changes in mice.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

P304

e23372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0023372

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Ryan J. Castoro

Jean-Pierre J Issa

P577

2011-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51586898

http://www.w3.org/2001/XMLSchema#string

P698

21858090

http://www.w3.org/2001/XMLSchema#string

P932

3157379

http://www.w3.org/2001/XMLSchema#string